University of Texas's MD Anderson Cancer Center: Patients with refractory metastatic colorectal cancer experience survival benefits with fruquintinib
September 12, 2022
September 12, 2022
HOUSTON, Texas, Sept. 12 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
MD Anderson presents results from Phase III FRESCO-2 trial at ESMO 2022
* * *
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with . . .
* * *
MD Anderson presents results from Phase III FRESCO-2 trial at ESMO 2022
* * *
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with . . .